Suppr超能文献

原发性高草酸尿症或与草酸盐沉着症无关的肾衰竭患者草酸盐的骨含量。

Bony content of oxalate in patients with primary hyperoxaluria or oxalosis-unrelated renal failure.

作者信息

Marangella M, Vitale C, Petrarulo M, Tricerri A, Cerelli E, Cadario A, Barbos M P, Linari F

机构信息

Renal Stone Laboratory, Mauriziano Hospital, Torino, Italy.

出版信息

Kidney Int. 1995 Jul;48(1):182-7. doi: 10.1038/ki.1995.283.

Abstract

Oxalate retention occurs in end-stage renal failure. Regular dialysis treatment does not prevent progressive accumulation of oxalate in cases of ESRF due to primary hyperoxaluria (PH), whereas such accumulation seldom seems to occur in oxalosis-unrelated ESRF. To elucidate this issue we have measured the bony content of oxalate on biopsies of the iliac crest taken from 32 uremic patients, 7 of them with ESRF associated with PH1 (6 cases) or PH2 (1 case). Ten subjects with normal renal function and no evidence of metabolic bone disease were taken as controls. Only trace amounts levels of oxalate were detected in normal subjects and oxalate to phosphate ratio was below 3:10,000. Non-PH dialyzed patients exhibited fivefold increases in oxalate levels, which rose to 5.1 +/- 3.6 mumol/g bony tissue. Calcium oxalate was estimated to represent 0.18% of the hydroxyapatite content of bone. Oxalate amounts were neither related to pre-dialysis plasma levels of oxalate, nor with duration of dialysis treatment, suggesting that accumulation was not progressive disorder. Oxalate levels were slightly higher in patients with a low turnover osteodystrophy compared to those with a high turnover pattern. Dialyzed patients with PH had remarkable increases in oxalate levels, which ranged between 14.8 and 907 mumol/g bony tissue. Oxalate deposition appeared to be progressive in that oxalate levels were significantly related to time on dialysis. In three patients calcium oxalate was a significant fraction of the mineralized bone. The occurrence of calcium oxalate crystals affected the histomorphometric patterns, that were featured by an increase in resorptive areas and a decrease in bone formation rate.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

草酸盐潴留发生于终末期肾衰竭。对于因原发性高草酸尿症(PH)导致的终末期肾衰竭患者,常规透析治疗无法阻止草酸盐的逐渐蓄积,而在与草酸盐沉着症无关的终末期肾衰竭病例中,这种蓄积似乎很少发生。为阐明这一问题,我们测量了32例尿毒症患者髂嵴活检组织中的草酸盐骨含量,其中7例患者的终末期肾衰竭与1型原发性高草酸尿症(6例)或2型原发性高草酸尿症(1例)相关。选取10名肾功能正常且无代谢性骨病证据的受试者作为对照。在正常受试者中仅检测到痕量水平的草酸盐,草酸盐与磷酸盐的比率低于3:10,000。非PH透析患者的草酸盐水平增加了五倍,升至5.1±3.6μmol/g骨组织。草酸钙估计占骨羟基磷灰石含量的0.18%。草酸盐含量既与透析前血浆草酸盐水平无关,也与透析治疗时间无关,这表明蓄积并非进行性疾病。与高转换型骨营养不良患者相比,低转换型骨营养不良患者的草酸盐水平略高。患有PH的透析患者草酸盐水平显著升高,范围在14.8至907μmol/g骨组织之间。草酸盐沉积似乎是进行性的,因为草酸盐水平与透析时间显著相关。在三名患者中,草酸钙是矿化骨的重要组成部分。草酸钙晶体的出现影响了组织形态计量学模式,其特征是吸收面积增加和骨形成率降低。(摘要截短于250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验